Imunotac 2mg Capsule contains Tacrolimus, a potent immunosuppressive agent primarily used to prevent organ transplant rejection. Tacrolimus functions by inhibiting calcineurin, thereby suppressing T-lymphocyte activation and reducing immune response. This mechanism is critical in post-transplant patients to prevent graft rejection and improve transplant survival. Imunotac is indicated for the prophylaxis of organ rejection in patients receiving liver, kidney, or heart transplants. The 2mg dosage form facilitates individualized dosing based on patient weight, organ type, and therapeutic drug monitoring. Administration should be under strict medical supervision due to the narrow therapeutic index and potential for serious adverse effects, including nephrotoxicity, neurotoxicity, hypertension, and increased susceptibility to infections. Regular monitoring of blood tacrolimus levels, renal function, and blood pressure is essential to optimize therapy and minimize toxicity. Concomitant use with other nephrotoxic or immunosuppressive agents requires caution. Patients should be advised to report signs of infection or unusual symptoms promptly. Imunotac should be stored at controlled room temperature, protected from moisture and light. This medication is contraindicated in patients with hypersensitivity to tacrolimus or any formulation components. Proper adherence to prescribed dosing and monitoring protocols is vital to achieve therapeutic efficacy and enhance transplant outcomes.